Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Journal of antimicrobial chemotherapy
- Publicado em
- 4 nov 2025
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study
Thibaut Gelé, Daniel Atwine, Elisabeth Baudin, Winnie Muyindike, Kenneth Mworozi, Racheal Kyohairwe, Keneth Kananura, Susan Logoose, Dan Nyehangane, Deborah K T Nanjebe et al.
Descritores MeSH
- Rifampin
- Tuberculosis
- Isoniazid
- HIV Infections
- Anti-HIV Agents
- Benzoxazines
- Antitubercular Agents
- Coinfection
- Plasma
- Uganda
Veja também
Estudos relacionados
- Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid
- Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
- Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
- O efeito da metformina na farmacocinética da rifampicina, isoniazida e pirazinamida em adultos com tuberculose